MIP Technologies and FeF Chemicals sign Research and Development Agreement

25-Jan-2005

MIP Technologies AB, a developer of molecular molecularly imprinted polymers for separations and drug discovery, announced that it has signed a research and development agreement with FeF Chemicals, a subsidiary of Novo Nordisk. During this program of work, MIP Technologies will develop for FeF a novel separation material with the potential for use in large scale protein purification. Under the terms of the Agreement, MIP Technologies will receive R&D funding including milestone payments, while FeF/Novo Nordisk will receive a license for manufacturing and use of the new material. MIP Technologies will retain the rights to use this new material in all fields with the exception of applications in diabetes.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances